Massive MS registry launches to uncover Real-World treatment outcomes

NCT ID NCT03291756

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: CorEvitas Source: ClinicalTrials.gov ↗

First seen Feb 22, 2026 · Last updated May 15, 2026 · Updated 12 times

Summary

This study will follow 1,000 adults with multiple sclerosis (MS) who are starting a new MS medication. Researchers will track side effects, relapses, and daily function over time to see how well different treatments work in routine medical practice. The goal is to gather real-world evidence to help doctors and patients make better treatment decisions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CorEvitas, LLC

    Waltham, Massachusetts, 02451, United States

Conditions

Explore the condition pages connected to this study.